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Abstract Identifying patients with germline MUTYH
mutation-associated polyposis is presently difficult. The
aim of this study is to investigate the possibilities of IHC as
a screening test to select patients for MUTYH mutation
analysis. The expression of MUTYH protein in colorectal
adenomas or cancer was studied by IHC using three
different (1 polyclonal and 2 monoclonal) antibodies in
six samples from patients with biallelic MUTYH mutations,
in three samples from patients with a single MUTYH
mutation, and in 11 samples from patients without MUTYH
mutations. With the polyclonal antibody, adenomas and
carcinomas from patients with biallelic MUTYH mutations
showed a strong supranuclear cytoplasmic staining without
epithelial nuclear staining. The strong supranuclear staining
was also observed in the three samples from patients with a
single MUTYH mutation and in nine out of 11 samples from
patients without MUTYH mutations, with or without
nuclear staining. Samples incubated with the monoclonal
antibodies showed a non-specific pattern. Our results
demonstrate that, in contrast with previous data, the
cytoplasmic staining in neoplastic cells does not discrimi-
nate MUTYH mutated from unmutated cases. At present,
IHC cannot be used in clinical practice to differentiate
between colorectal tissue with and without germline
MUTYH mutations.
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Abbreviations
CRC Colorectal cancer
MUTYH MUTY homolog
MAP MUTYH-associated polyposis
BER Base excision repair
IHC Immunohistochemistry
MSS Microsatellite stable
Introduction
MUTYH-associated polyposis (MAP) is an autosomal-
recessive disease characterized by multiple colorectal
adenomas and cancer [1]. Approximately 30% of patients
with more than15 adenomas that do not carry pathogenic
APC mutations are biallelic MUTYH mutation carriers [2].
MAP was first reported in a British family, in which three
affected siblings were compound heterozygote for MUTYH
mutations [1]. MUTYH acts together with OGG1 and
MTH1 in the base excision repair (BER) system, a repair
system to defend cellular DNA against the mutagenic
effects of 7,8-dihydro-8-oxoguanine (8-oxoG) [2, 3]. 8-
OxoG easily mispairs with adenine residues leading to G:
C→T:A transversion mutations in the daughter strand [1,
4]. Normally, MUTYH is expressed in mitochondria and in
the nuclei of human cells [5].
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Identification of patients with biallelic MUTYH
mutation-associated polyposis is important to target effective
preventive measures for patients and their families, which
may lead to reduction in CRC-related mortality. DNA
mutation analysis can determine the possible genetic cause
of polyposis. To avoid expensive, unnecessary, and time-
consuming DNA mutation analyses, there is a need for a
screening test to select individuals eligible for DNA mutation
analysis.
Immunohistochemical analysis is a rapid and inexpen-
sive method, useful for a wide range of diseases. In a recent
study by Di Gregorio et al., immunohistochemical staining
of MUTYH protein was performed to identify patients with
MAP [6]. A specific pattern of staining for the MUTYH
protein was seen; unlike in patients without MUTYH
mutations, patients with biallelic MUTYH mutations
showed absence of nuclear staining and segregation of
immune reactivity in the cytoplasm (supranuclear staining),
both in neoplastic and surrounding healthy mucosa [6].
Therefore, tissues from patients with and without mutations
might be distinguished from each other. Consequently, IHC
could be used to identify patients with MUTYH-associated
polyposis. The aim of this study is to further investigate the
possibilities of immunohistochemistry as a pre-screening
test to select patients for MUTYH mutation analysis.
Materials and methods
The study included 20 samples from 19 patients, divided
into three groups. Samples were collected in five different
pathology laboratories in different hospitals in the Nether-
lands (Radboud University Nijmegen Medical Center;
Rijnstaete Hospital, Arnhem; Amphia Medical Center,
Breda; Jeroen Bosch Hospital, Den Bosch; MedischSpec-
trum Twente, Enschede).
Group 1 consists of five patients carrying biallelic
MUTYH mutations (six samples from colorectal carcinoma
or adenoma); an overview of the clinical features and
mutations of these patients is given in Table 1. All patients
were compound heterozygous for pathogenic mutations in
MUTYH. Mutation analysis of MUTYH was performed, in
the Leiden University Medical Center, as described by
Nielsen et al. [7], with sequence analysis of exon 1 till 16.
Group 2 consists of 11 patients with polyposis or CRC
without detectable mutations in MUTYH (11 samples from
adenoma or CRC). Group 3 consists of three patients
carrying a monoallelic MUTYH mutation (with three
samples from adenomas and normal mucosa).
Immunohistochemical staining was performed on 4-μm-
thick, formalin-fixed, paraffin-embedded tissue sections
that were prepared on coated slides and dried for 30 min
Table 1 Clinical features of patients with MUTYH-associated polyposis, the type biallelic mutations, and the immunoreactivity pattern of
MUTYH protein, using the Abcam antibody
Patient Number
of adenomas
Sex Age Analyzed
samples
Grading/
differentiationa
Site Mutation MUTYH Type of
mutation
Supranuclear
stainingb
Epithelial
nuclear
stainingc
1 >100 M 48 Adenoma cancer
(T4N0)
Low grade G2 Asc. colon
sigmoid
c.697C>T, p.
Arg233X
c.1172C>T,
p.Pro391Leu
Nonsense 1 0
Missense
2 >50 F 47 Adenoma Low grade Rectum c.494A>G, p.
Tyr165Cys
c.1172C>T,
p.Pro391Leu
Missense 1 0
Missense
3 50 M 48 Cancer (T3N0) G2 Cecum c.494A>G, p.
Tyr165Cys
c.1145G>A,
p.Gly382Asp
Missense 1 0
Missense
4 40–50 M 46 Cancer (T3N0) G2 Cecum c.697C>T p.
Arg233X
c.1145G>A
p.Gly382Asp
Nonsense 1 0
Missense
5 >10 M 48 Adenoma Low grade Desc. colon c.1145G>A,
p.Gly382Asp
c.1172C>T,
p.Pro391Leu
Missense 1 0
Missense
a Differentiation for carcinomas: G1 well differentiated, G2 moderately differentiated, G3 poorly differentiated, G4 undifferentiated
b 0=absent, 1=present
c 0=no staining, 1=minimal to mild staining (<10–50% section MUTYH positive), 2=strong staining (>50% section MUTYH positive)
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at 55°C. Tissue sections were deparaffinized in xylene and
rehydrated with alcohol. Antigen retrieval was done by boiling
in 10 mM citrate buffer (PH 6) for 10 min at 95°C.
Endogenous peroxidase activity was blocked by exposing the
slides to 3% H2O2 in methanol for 10 min. Then, sections
were incubated with primary MUTYH antibody overnight at
4°C. Polyclonal MUTYH antibody (residues 531–546,
Abcam, Cambridge, UK) at 1:300, primary polyclonal
MUTYH antibody (residues 33–51, Calbiochem) at 1:1,600,
and primary monoclonal MutYH antibody (clone 4D10,
Abnova Corporation) at 1:200 were used. These dilutions
were determined after examining several dilution series, to
obtain the best results. Next, sections were incubated with
Poly-HRP-GAM/R/R IgG for 30 min. Visualizing was done
with DAB for 5 min. Nuclei were counterstained with
hematoxylin. Slides were dehydrated, cleared in xylene, and
mounted with micromount.
Normal immunoreactivity of the MUTYH protein was
defined as the presence of nuclear and light cytoplasmic
staining. Altered expression was considered when the cells
showed disappearance of staining from the nucleus and
instead showed supranuclear staining. Staining for
MUTYH in the nucleus was evaluated by the scoring
system Gao et al. reported: 0=no staining; 1=minimal to
mild staining (10–50% section positive); 2=strong staining
(>50% section positive) [8]. Cytoplasmic staining was
classified as present or absent.
Results
With the polyclonal antibody, adenomas and carcinomas of
all patients with MUTYH biallelic mutations showed strong
supranuclear cytoplasmic staining, without nuclear expres-
sion of protein (Table 1). Adjacent normal mucosa, in
patients with biallelic MUTYH mutations, showed the same
pattern of expression found in adenomas and carcinomas.
As shown in Fig. 1, supranuclear cytoplasmic staining was
localized at the apex of the colonocytes (a) or neoplastic cells
(b). The 11 samples of colorectal tissue of patients without
MUTYH mutations, incubated with the polyclonal antibody,
showed several patterns (Table 2 and Fig. 2). Nine samples
showed the supranuclear cytoplasmic staining described
above of which five had weak and four no epithelial nuclear
staining. Two samples did not show the supranuclear
cytoplasmic staining; they showed weak nuclear and weak
cytoplasmic staining. All three samples of colon tissue of
patients with one MUTYH mutation showed supranuclear
staining; additionally, two showed also nuclear staining.
Diffuse cytoplasmic staining was observed in some
samples either with or without MUTYH mutations; the
intensity was always weak. From these results, we conclude
that we could not differentiate between tissue with or
without MUTYH mutations, while using the polyclonal
antibody.
Two monoclonal antibodies were used to evaluate the
MUTYH protein staining pattern as well. Samples incubated
with the Calbiochem antibody showed strong nuclear and
cytoplasmic staining for all tissue regardless whether
MUTYH mutations were present. Samples incubated with
the Abnova antibody showed no epithelial nuclear or
cytoplasmic staining at all; however, nuclear staining was
observed in stroma cells. This pattern was the same for tissue
with and without MUTYH mutations.
Discussion
Using the commercially available polyclonal antibody for
MUTYH, cytoplasmic staining in neoplastic cells does not
discriminate MUTYH-mutated samples from unmutated
Fig. 1 Strong epithelial supranuclear cytoplasmic immunoreactivity
and absence of nuclear expression of MUTYH protein in a normal
mucosa (original magnification, ×500) and b carcinoma (original
magnification, ×100) of patients with biallelic MUTYH mutations.
Note nuclear staining in some stromal fibroblasts
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cases; presence of nuclear staining excludes the MUTYH
mutation, but is of limited specificity. Samples incubated
with the Calbiochem or Abnova antibody showed a non-
specific pattern since no differentiation was possible
between tissue with and without MUTYH mutations.
Consequently, the two other antibodies did not seem to
work on formalin-fixed, paraffin-embedded tissue after
using different pretreatments and dilutions. There are no
indications that, with the present mutation analysis of
MUTYH, mutations are being missed (reported by C.M.J.
Tops, Center for Human and Clinical Genetics, Leiden
University Medical Center).
There are just a few immunohistochemical studies of the
MUTYH protein described. Di Gregorio et al. described
that tissue of patients with biallelic MUTYH mutations
showed absence of nuclear staining and segregation of
immunoreactivity (supranuclear) in the cytoplasm [6]. Their
hypothesis for this pattern was that the protein produced by
the mutated gene could lack the capacity to transfer into the
nucleus and remain trapped in the cytoplasm [6]. Our
results confirm this finding, but importantly we show that
this pattern of staining does not distinguish between tissue
of patients with and without MUTYH mutations. Recently,
O’Shea et al. published results more consistent with our
own, showing MUTYH immunohistochemistry not dis-
criminating controls, biallelic, and heterozygote MUTYH
mutation carriers [9].
Koketsu et al. showed that loss of expression of the BER
proteins, MUTYH, MTH1, and NTH1 occurs in sporadic
colorectal cancer [10]. Nuclear MUTYH immunoreactivity
was detected in only 57% of cases (46/81) [10]. They
described that the presence of nuclear MUTYH expression
showed a significant correlation with the T-stage of the
tumor (p=0.04) [10].
Further, it is not clear whether MUTYH protein is always
expressed in the nucleus. Boldogh et al. showed that the
majority of MUTYH protein was distributed in the cytoplasm,
which is in agreement with a mitochondrial association of
MUTYH, and that in only a small percentage (3–5%) of the
cells MUTYH-specific fluorescence was also localized to the
nuclei [11]. These findings are in contrast with the data of
Tsai-Wu et al. which suggest that the MUTYH protein is
mainly nuclear specific, based on their own polyclonal rabbit
antibodies [12]. Recently, it was shown by Van Puijenbroek
et al. that somatic KRAS2 mutation testing of carcinomas can
successfully be used as a pre-screening test for germline
MUTYH mutation analysis [13].
In conclusion, our results demonstrate that, in contrast
with the findings of Di Gregorio et al., while using the same
methods and two additional antibodies, cytoplasmic expres-
sion of the MUTYH protein is not specific for germline
MUTYH mutation. At present, immunohistochemistry can-
not be used in clinical practice to differentiate between
colorectal tissue with and without MUTYH mutations.
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Table 2 Clinical features of patients without MUTYH-associated polyposis, the mutations tested, and the immunoreactivity pattern, using the
Abcam antibody
Patient Number of
adenomas
Sex Age Analyzed
samples
MUTYH
mutations
APC
mutations
Mis-match repair
deficiency
PTEN Supranuclear
staininga
Epithelial nuclear
stainingb
Polyposis
6 >50 M 79 Cancer Neg Negc NDd ND 1 0
7 >20 M 58 Adenoma Neg Neg ND ND 0 1
8 >10 M 62 Adenoma Neg Neg ND ND 1 1
9 >10 M 45 Adenoma Neg Neg MSSe ND 1 0
10 >10 M 60 Adenoma Neg Neg MSS ND 0 1
11 >10 F 44 Adenoma Neg Neg MSS ND 1 0
12 >10 F 56 Adenoma Neg Neg MSS ND 1 1
Non-polyposis
13 10 M 61 Adenoma Neg ND ND ND 1 1
14 <10 F 41 Adenoma Neg ND ND ND 1 1
15 2 F 49 Adenoma Neg Neg MSS Neg 1 0
16 0 M 43 Normal tissue Neg Neg MSS Neg 1 1
a 0=absent, 1=present
b 0 =no staining, 1=minimal to mild staining (<10–50% section MUTYH positive), 2=strong staining (>50% section MUTYH positive)
cNeg tested negative
dND not determined
eMSS microsatellite stable
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